Gossamer Bio (NASDAQ:GOSS) Receives Buy Rating from HC Wainwright

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright also issued estimates for Gossamer Bio’s FY2029 earnings at $0.59 EPS.

Gossamer Bio Trading Up 3.1 %

Shares of NASDAQ GOSS opened at $0.99 on Thursday. The stock has a market capitalization of $225.15 million, a P/E ratio of -3.11 and a beta of 1.81. Gossamer Bio has a 1-year low of $0.50 and a 1-year high of $1.60. The business’s 50 day moving average is $0.87 and its two-hundred day moving average is $0.90. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $4.52 million. As a group, research analysts expect that Gossamer Bio will post -0.28 EPS for the current year.

Institutional Investors Weigh In On Gossamer Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GOSS. Marshall Wace LLP increased its position in shares of Gossamer Bio by 170.8% during the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock worth $3,002,000 after acquiring an additional 2,103,766 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Gossamer Bio by 204.7% in the second quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company’s stock valued at $1,844,000 after purchasing an additional 1,375,000 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in Gossamer Bio by 30.7% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after purchasing an additional 442,895 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Gossamer Bio by 24.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after purchasing an additional 74,920 shares during the period. Finally, Sequoia Financial Advisors LLC raised its position in Gossamer Bio by 26.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after purchasing an additional 25,000 shares in the last quarter. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.